Herpes Virus
| Property | Information |
|---|---|
| Drug Name | Herpes Virus |
| FDA Approval | Not specified |
| Used for | Not specified |
| Clinical Trial Phase | Not specified |
| Clinical Trial Explanation | Not specified |
| Common Side Effects | Not specified |
| OS without | Not specified |
| OS with | Not specified |
| PFS without | Not specified |
| PFS with | Not specified |
| Usefulness Rating | Not rated |
| Usefulness Explanation | Not specified |
| Toxicity Level | Not specified |
| Toxicity Explanation | Not specified |
From Ben Williams Book: Another virus used in cancer therapy is a modified form of the herpes virus. Initial trials used a retrovirus version, which infects only those cells dividing when the virus was infused. Subsequent trials have used an adenovirus version, which infects both dividing and non-dividing cells. Because the herpes virus can be lethal to the brain if allowed to proliferate, soon after the virus infusion patients receive ganciclovir, an effective anti-herpes agent. In one study using this technique performed at Mt. Sinai Hospital in New York (170), median survival of 12 patients with recurrent GBM tumors was 59 weeks from the point of treatment, with 50% of the patients alive 12 months after the treatment. The authors also reported the absence of toxicity from the treatment, which was a major concern due to significant brain damage when the procedure was tested with monkeys. Why the difference from the monkey study's results is unclear.
More recent research with the herpes virus has been focused on forms of the virus that have been engineered to retain the anti-cancer effects of the virus but without its property of producing neurological inflammation. The first use of this modified virus in a clinical trial was in Glasgow, Scotland. Nine patients with recurrent glioblastomas received the virus injected directly into the tumor. Four were alive at the time of the report of the study, 14-24 months after the treatment (171).Property "Has original text" (as page type) with input value "Another virus used in cancer therapy is a modified form of the herpes virus. Initial trials</br>used a retrovirus version, which infects only those cells dividing when the virus was</br>infused. Subsequent trials have used an adenovirus version, which infects both dividing</br>and non-dividing cells. Because the herpes virus can be lethal to the brain if allowed to</br>proliferate, soon after the virus infusion patients receive ganciclovir, an effective</br>anti-herpes agent. In one study using this technique performed at Mt. Sinai Hospital in</br>New York (170), median survival of 12 patients with recurrent GBM tumors was 59 weeks</br>from the point of treatment, with 50% of the patients alive 12 months after the treatment.</br>The authors also reported the absence of toxicity from the treatment, which was a major</br>concern due to significant brain damage when the procedure was tested with monkeys.</br>Why the difference from the monkey study's results is unclear.</br></br>More recent research with the herpes virus has been focused on forms of the virus that</br>have been engineered to retain the anti-cancer effects of the virus but without its property</br>of producing neurological inflammation. The first use of this modified virus in a clinical</br>trial was in Glasgow, Scotland. Nine patients with recurrent glioblastomas received the</br>virus injected directly into the tumor. Four were alive at the time of the report of the</br>study, 14-24 months after the treatment (171)." contains invalid characters or is incomplete and therefore can cause unexpected results during a query or annotation process.
